Beau Ances on amyloid biomarkers in Alzheimer...

In this episode of In Conversation With, Morgane Boillot, Senior Editor at The Lancet Neurology, speaks with connective tissue disorders — including Marfan syndrome — and human genetics expert Hal Dietz from Johns Hopkins Medicine (Baltimore, USA) about the genetics of spontaneou ...  Show more

In this episode of In Conversation With, Elena Becker-Barroso, Editor-in-Chief of The Lancet Neurology, speaks with movement disorders specialist Tony Schapira from UCL’s Queen Square Institute of Neurology about GBA1-associated Parkinson’s disease. Together, they explore the gen ...  Show more

Dr. Rae Bacharach discusses the Neurology Today article, "Individuals Can Now Request a Blood Test for Alzheimer disease - Why Some Dementia Experts Are Wary". Show references: https://journals.lww.com/neurotodayonline/fulltext/2023/10190/individuals_can_now_request_a_blood_test_ ...  Show more

In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease.

<stron ...

What are Biomarkers? And why are they useful in Alzheimer's Disease Research. 

Dr. Manisha Bahl interviews Dr. Jeffrey Prescott. Diffuse Tensor MRI Structural Connectivity and PET Amyloid Burden in Preclinical Autosomal Dominant Alzheimer Disease: The DIAN Cohort. Prescott et al. Radiology 2022; 302:143–150.